[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"$fTN4uSJ2HvK6Ky3QNAnhyq5f6JYu3cffiQe-Iqyl1xnc":3},{"sponsor":4,"sponsorVariants":5,"totalTrials":6,"truncated":7,"activeTrials":8,"phase3Count":9,"totalEnrollment":10,"activePrograms":11,"nonDrugCount":12,"topConditions":13,"upcomingReadouts":34,"phaseBuckets":55,"rows":62},"Advancing Clinical Therapeutics Globally for HIV\u002FAIDS and Other Infections",[4],70,false,6,8,45242,7,14,[14,17,20,22,24,26,29,32],{"name":15,"count":16},"HIV-1 Infection",30,{"name":18,"count":19},"HIV Infections",22,{"name":21,"count":11},"HIV Infection",{"name":23,"count":11},"Tuberculosis",{"name":25,"count":8},"HIV-1-infection",{"name":27,"count":28},"Hepatitis C",2,{"name":30,"count":31},"Tuberculosis, Pulmonary",1,{"name":33,"count":31},"Hepatitis",[35,40,45,50],{"nctId":36,"briefTitle":37,"date":38,"intervention":39},"NCT06031272","Pausing Antiretroviral Treatment Under Structured Evaluation","2025-10-14","3BNC117-LS-J",{"nctId":41,"briefTitle":42,"date":43,"intervention":44},"NCT06856174","Menopausal HT for Women Living With HIV (HoT)","2027-09-20","Transdermal estradiol gel",{"nctId":46,"briefTitle":47,"date":48,"intervention":49},"NCT06205589","Therapeutic ID93 + GLA-SE Vaccination in Participants With Rifampicin-Susceptible Pulmonary TB","2028-10-31","ID93 + GLA-SE vaccine",{"nctId":51,"briefTitle":52,"date":53,"intervention":54},"NCT06205602","Antiretrovirals Combined With Antibodies for HIV-1 Cure In Africa","2029-02-16","3BNC117-LS",[56,57,58,59,60,61],"EARLY_PHASE1","PHASE1","PHASE2","PHASE3","PHASE4","NA",[63,87,105,126,144,166,189,207,290,350,383,411,429,447,465,483,501,519,545,569,596,614,632,650,668,693,731,763,793,815,844,862,880,898,923,941,959,977,995,1013,1039,1057,1108,1130,1165,1187,1209,1232,1257,1281,1304,1328,1352,1378,1403,1421,1439,1467,1485,1503,1521,1539,1557,1583,1608,1631,1655,1673,1691,1714,1732,1756,1774,1798,1822,1840,1858,1876,1894,1912,1935,1959,1977,1995,2013,2031,2107,2145,2183,2219,2249,2279,2309,2335,2357,2385],{"intervention":44,"totalTrials":31,"cells":64},{"EARLY_PHASE1":65,"PHASE1":68,"PHASE2":70,"PHASE3":72,"PHASE4":74,"NA":85},{"trials":66,"activeCount":67},[],0,{"trials":69,"activeCount":67},[],{"trials":71,"activeCount":67},[],{"trials":73,"activeCount":67},[],{"trials":75,"activeCount":31,"soonestReadout":43},[76],{"nctId":41,"briefTitle":42,"status":77,"phases":78,"primaryCompletion":43,"completion":43,"start":79,"enrollment":80,"conditions":81,"interventions":83},"RECRUITING",[60],"2026-04-09",105,[21,82],"Menopause",[44,84],"Micronized Progesterone",{"trials":86,"activeCount":67},[],{"intervention":84,"totalTrials":31,"cells":88},{"EARLY_PHASE1":89,"PHASE1":91,"PHASE2":93,"PHASE3":95,"PHASE4":97,"NA":103},{"trials":90,"activeCount":67},[],{"trials":92,"activeCount":67},[],{"trials":94,"activeCount":67},[],{"trials":96,"activeCount":67},[],{"trials":98,"activeCount":31,"soonestReadout":43},[99],{"nctId":41,"briefTitle":42,"status":77,"phases":100,"primaryCompletion":43,"completion":43,"start":79,"enrollment":80,"conditions":101,"interventions":102},[60],[21,82],[44,84],{"trials":104,"activeCount":67},[],{"intervention":54,"totalTrials":31,"cells":106},{"EARLY_PHASE1":107,"PHASE1":109,"PHASE2":111,"PHASE3":120,"PHASE4":122,"NA":124},{"trials":108,"activeCount":67},[],{"trials":110,"activeCount":67},[],{"trials":112,"activeCount":31,"soonestReadout":53},[113],{"nctId":51,"briefTitle":52,"status":77,"phases":114,"primaryCompletion":53,"completion":53,"start":115,"enrollment":116,"conditions":117,"interventions":118},[58],"2025-01-17",135,[25],[54,119],"10-1074-LS",{"trials":121,"activeCount":67},[],{"trials":123,"activeCount":67},[],{"trials":125,"activeCount":67},[],{"intervention":119,"totalTrials":31,"cells":127},{"EARLY_PHASE1":128,"PHASE1":130,"PHASE2":132,"PHASE3":138,"PHASE4":140,"NA":142},{"trials":129,"activeCount":67},[],{"trials":131,"activeCount":67},[],{"trials":133,"activeCount":31,"soonestReadout":53},[134],{"nctId":51,"briefTitle":52,"status":77,"phases":135,"primaryCompletion":53,"completion":53,"start":115,"enrollment":116,"conditions":136,"interventions":137},[58],[25],[54,119],{"trials":139,"activeCount":67},[],{"trials":141,"activeCount":67},[],{"trials":143,"activeCount":67},[],{"intervention":49,"totalTrials":31,"cells":145},{"EARLY_PHASE1":146,"PHASE1":148,"PHASE2":150,"PHASE3":160,"PHASE4":162,"NA":164},{"trials":147,"activeCount":67},[],{"trials":149,"activeCount":67},[],{"trials":151,"activeCount":31,"soonestReadout":48},[152],{"nctId":46,"briefTitle":47,"status":153,"phases":154,"primaryCompletion":48,"completion":155,"start":156,"enrollment":157,"conditions":158,"interventions":159},"NOT_YET_RECRUITING",[58],"2029-10-13","2026-07-01",1500,[30],[49],{"trials":161,"activeCount":67},[],{"trials":163,"activeCount":67},[],{"trials":165,"activeCount":67},[],{"intervention":39,"totalTrials":31,"cells":167},{"EARLY_PHASE1":168,"PHASE1":170,"PHASE2":181,"PHASE3":183,"PHASE4":185,"NA":187},{"trials":169,"activeCount":67},[],{"trials":171,"activeCount":31,"soonestReadout":38},[172],{"nctId":36,"briefTitle":37,"status":173,"phases":174,"primaryCompletion":38,"completion":175,"start":176,"enrollment":177,"conditions":178,"interventions":179},"ACTIVE_NOT_RECRUITING",[57],"2026-06-30","2024-05-28",32,[25],[39,180],"10-1074-LS-J",{"trials":182,"activeCount":67},[],{"trials":184,"activeCount":67},[],{"trials":186,"activeCount":67},[],{"trials":188,"activeCount":67},[],{"intervention":180,"totalTrials":31,"cells":190},{"EARLY_PHASE1":191,"PHASE1":193,"PHASE2":199,"PHASE3":201,"PHASE4":203,"NA":205},{"trials":192,"activeCount":67},[],{"trials":194,"activeCount":31,"soonestReadout":38},[195],{"nctId":36,"briefTitle":37,"status":173,"phases":196,"primaryCompletion":38,"completion":175,"start":176,"enrollment":177,"conditions":197,"interventions":198},[57],[25],[39,180],{"trials":200,"activeCount":67},[],{"trials":202,"activeCount":67},[],{"trials":204,"activeCount":67},[],{"trials":206,"activeCount":67},[],{"intervention":208,"totalTrials":209,"cells":210},"Efavirenz",5,{"EARLY_PHASE1":211,"PHASE1":213,"PHASE2":215,"PHASE3":232,"PHASE4":249,"NA":288},{"trials":212,"activeCount":67},[],{"trials":214,"activeCount":67},[],{"trials":216,"activeCount":67},[217],{"nctId":218,"briefTitle":219,"status":220,"phases":221,"primaryCompletion":222,"completion":222,"start":223,"enrollment":224,"conditions":225,"interventions":227},"NCT01632891","Comparing PI-Based to a nNRTI-based ART for Clearance of Plasmodium Falciparum Parasitemia in HIV-Infected","COMPLETED",[57,58],"2016-06-19","2014-01-10",52,[15,226],"Pf Subclinical Parasitemia",[228,229,208,230,231],"Lopinavir\u002Fritonavir","Emtricitabine\u002Ftenofovir disoproxil fumarate","Nevirapine","Trimethoprim\u002Fsulfamethoxazole",{"trials":233,"activeCount":67},[234],{"nctId":235,"briefTitle":236,"status":220,"phases":237,"primaryCompletion":238,"completion":238,"start":239,"enrollment":240,"conditions":241,"interventions":242},"NCT00118898","Efavirenz or Atazanavir\u002FRitonavir Given With Emtricitabine\u002FTenofovir Disoproxil Fumarate or Abacavir\u002FLamivudine in HIV Infected Treatment-Naive Adults",[59],"2009-11","2005-09",1864,[18],[243,244,208,245,246,247,248],"Abacavir\u002FLamivudine","Atazanavir","Emtricitabine\u002FTenofovir disoproxil fumarate","Ritonavir","Abacavir\u002FLamivudine placebo","Emtricitabine\u002FTenofovir disoproxil fumarate placebo",{"trials":250,"activeCount":67},[251,261,276],{"nctId":252,"briefTitle":253,"status":220,"phases":254,"primaryCompletion":255,"completion":256,"start":257,"enrollment":258,"conditions":259,"interventions":260},"NCT00442962","HIV Treatment Reinitiation in Women Who Received Anti-HIV Drugs to Prevent Mother-to-Child Transmission of HIV",[60],"2010-07","2010-12","2007-05",54,[18],[208,245],{"nctId":262,"briefTitle":263,"status":220,"phases":264,"primaryCompletion":265,"completion":266,"start":267,"enrollment":268,"conditions":269,"interventions":270},"NCT01380080","REMEMBER: Reducing Early Mortality & Morbidity by Empiric Tuberculosis (TB) Treatment",[60],"2015-01-31","2016-04","2011-10",851,[21],[271,208,272,273,274,275],"Atripla","Truvada","Rifampin\u002Fisoniazid\u002Fpyrazinamide\u002Fethambutol FDC","Rifampin\u002Fisoniazid FDC","Isoniazid",{"nctId":277,"briefTitle":278,"status":220,"phases":279,"primaryCompletion":280,"completion":280,"start":281,"enrollment":282,"conditions":283,"interventions":284},"NCT00084136","Prospective Evaluation of Anti-retroviral Combinations for Treatment Naive, HIV Infected Persons in Resource-limited Settings",[60],"2010-05","2005-05",1571,[18],[244,285,208,286,245,287],"Didanosine","Emtricitabine","Lamivudine\u002FZidovudine",{"trials":289,"activeCount":67},[],{"intervention":275,"totalTrials":291,"cells":292},4,{"EARLY_PHASE1":293,"PHASE1":295,"PHASE2":297,"PHASE3":340,"PHASE4":342,"NA":348},{"trials":294,"activeCount":67},[],{"trials":296,"activeCount":67},[],{"trials":298,"activeCount":67},[299,313,323],{"nctId":300,"briefTitle":301,"status":220,"phases":302,"primaryCompletion":303,"completion":304,"start":305,"enrollment":306,"conditions":307,"interventions":308},"NCT01589497","Essentiality of INH in TB Therapy",[58],"2016-01-28","2016-02-10","2015-06-30",69,[23],[309,275,310,311,312],"Rifampicin","Pyrazinamide","Ethambutol","Moxifloxacin",{"nctId":314,"briefTitle":315,"status":220,"phases":316,"primaryCompletion":317,"completion":318,"start":319,"enrollment":320,"conditions":321,"interventions":322},"NCT01936831","High-Dose Isoniazid Among Adult Patients With Different Genetic Variants of INH-Resistant Tuberculosis (TB)",[58],"2021-09-22","2021-10-06","2014-08-13",282,[23],[275],{"nctId":324,"briefTitle":325,"status":326,"phases":327,"primaryCompletion":328,"completion":329,"start":330,"enrollment":331,"conditions":332,"interventions":333},"NCT01601626","Rifampin-Based Tuberculosis Treatment Versus Rifabutin-Based Tuberculosis Treatment in Persons With HIV","TERMINATED",[58],"2017-01-19","2017-06-28","2013-07-13",71,[21,23],[334,335,336,275,337,310,311,338,339],"Standard-dose Lopinavir\u002FRitonavir","Double-dose Lopinavir\u002FRitonavir","Raltegravir","Pyridoxine","Rifabutin","Rifampin",{"trials":341,"activeCount":67},[],{"trials":343,"activeCount":67},[344],{"nctId":262,"briefTitle":263,"status":220,"phases":345,"primaryCompletion":265,"completion":266,"start":267,"enrollment":268,"conditions":346,"interventions":347},[60],[21],[271,208,272,273,274,275],{"trials":349,"activeCount":67},[],{"intervention":287,"totalTrials":28,"cells":351},{"EARLY_PHASE1":352,"PHASE1":354,"PHASE2":356,"PHASE3":358,"PHASE4":375,"NA":381},{"trials":353,"activeCount":67},[],{"trials":355,"activeCount":67},[],{"trials":357,"activeCount":67},[],{"trials":359,"activeCount":67},[360],{"nctId":361,"briefTitle":362,"status":220,"phases":363,"primaryCompletion":364,"completion":364,"start":365,"enrollment":366,"conditions":367,"interventions":368},"NCT01352715","Study of Options for Second-Line Effective Combination Therapy (SELECT)",[59],"2014-10-29","2012-03-13",515,[15],[228,228,336,229,369,370,371,372,373,374],"Abacavir\u002Flamivudine\u002Fzidovudine","Abacavir\u002Flamivudine","Lamivudine\u002Fzidovudine","Abacavir","Zidovudine","Lamivudine",{"trials":376,"activeCount":67},[377],{"nctId":277,"briefTitle":278,"status":220,"phases":378,"primaryCompletion":280,"completion":280,"start":281,"enrollment":282,"conditions":379,"interventions":380},[60],[18],[244,285,208,286,245,287],{"trials":382,"activeCount":67},[],{"intervention":384,"totalTrials":31,"cells":385},"Etravirine",{"EARLY_PHASE1":386,"PHASE1":388,"PHASE2":390,"PHASE3":392,"PHASE4":394,"NA":409},{"trials":387,"activeCount":67},[],{"trials":389,"activeCount":67},[],{"trials":391,"activeCount":67},[],{"trials":393,"activeCount":67},[],{"trials":395,"activeCount":67},[396],{"nctId":397,"briefTitle":398,"status":220,"phases":399,"primaryCompletion":400,"completion":401,"start":402,"enrollment":403,"conditions":404,"interventions":405},"NCT01641367","A5288\u002FMULTI-OCTAVE: Management Using Latest Technologies to Optimize Combination Therapy After Viral Failure",[60],"2016-11-23","2018-12-31","2013-02-22",545,[15],[406,384,229,336,407,408],"Darunavir","Second line ART regimens - based on a boosted protease inhibitor","Study provided drugs according to patient resistance profile (DRV, ETR, RTV, FTC\u002FTDF) + any in country available drug as applicable & available",{"trials":410,"activeCount":67},[],{"intervention":407,"totalTrials":31,"cells":412},{"EARLY_PHASE1":413,"PHASE1":415,"PHASE2":417,"PHASE3":419,"PHASE4":421,"NA":427},{"trials":414,"activeCount":67},[],{"trials":416,"activeCount":67},[],{"trials":418,"activeCount":67},[],{"trials":420,"activeCount":67},[],{"trials":422,"activeCount":67},[423],{"nctId":397,"briefTitle":398,"status":220,"phases":424,"primaryCompletion":400,"completion":401,"start":402,"enrollment":403,"conditions":425,"interventions":426},[60],[15],[406,384,229,336,407,408],{"trials":428,"activeCount":67},[],{"intervention":408,"totalTrials":31,"cells":430},{"EARLY_PHASE1":431,"PHASE1":433,"PHASE2":435,"PHASE3":437,"PHASE4":439,"NA":445},{"trials":432,"activeCount":67},[],{"trials":434,"activeCount":67},[],{"trials":436,"activeCount":67},[],{"trials":438,"activeCount":67},[],{"trials":440,"activeCount":67},[441],{"nctId":397,"briefTitle":398,"status":220,"phases":442,"primaryCompletion":400,"completion":401,"start":402,"enrollment":403,"conditions":443,"interventions":444},[60],[15],[406,384,229,336,407,408],{"trials":446,"activeCount":67},[],{"intervention":271,"totalTrials":31,"cells":448},{"EARLY_PHASE1":449,"PHASE1":451,"PHASE2":453,"PHASE3":455,"PHASE4":457,"NA":463},{"trials":450,"activeCount":67},[],{"trials":452,"activeCount":67},[],{"trials":454,"activeCount":67},[],{"trials":456,"activeCount":67},[],{"trials":458,"activeCount":67},[459],{"nctId":262,"briefTitle":263,"status":220,"phases":460,"primaryCompletion":265,"completion":266,"start":267,"enrollment":268,"conditions":461,"interventions":462},[60],[21],[271,208,272,273,274,275],{"trials":464,"activeCount":67},[],{"intervention":272,"totalTrials":31,"cells":466},{"EARLY_PHASE1":467,"PHASE1":469,"PHASE2":471,"PHASE3":473,"PHASE4":475,"NA":481},{"trials":468,"activeCount":67},[],{"trials":470,"activeCount":67},[],{"trials":472,"activeCount":67},[],{"trials":474,"activeCount":67},[],{"trials":476,"activeCount":67},[477],{"nctId":262,"briefTitle":263,"status":220,"phases":478,"primaryCompletion":265,"completion":266,"start":267,"enrollment":268,"conditions":479,"interventions":480},[60],[21],[271,208,272,273,274,275],{"trials":482,"activeCount":67},[],{"intervention":273,"totalTrials":31,"cells":484},{"EARLY_PHASE1":485,"PHASE1":487,"PHASE2":489,"PHASE3":491,"PHASE4":493,"NA":499},{"trials":486,"activeCount":67},[],{"trials":488,"activeCount":67},[],{"trials":490,"activeCount":67},[],{"trials":492,"activeCount":67},[],{"trials":494,"activeCount":67},[495],{"nctId":262,"briefTitle":263,"status":220,"phases":496,"primaryCompletion":265,"completion":266,"start":267,"enrollment":268,"conditions":497,"interventions":498},[60],[21],[271,208,272,273,274,275],{"trials":500,"activeCount":67},[],{"intervention":274,"totalTrials":31,"cells":502},{"EARLY_PHASE1":503,"PHASE1":505,"PHASE2":507,"PHASE3":509,"PHASE4":511,"NA":517},{"trials":504,"activeCount":67},[],{"trials":506,"activeCount":67},[],{"trials":508,"activeCount":67},[],{"trials":510,"activeCount":67},[],{"trials":512,"activeCount":67},[513],{"nctId":262,"briefTitle":263,"status":220,"phases":514,"primaryCompletion":265,"completion":266,"start":267,"enrollment":268,"conditions":515,"interventions":516},[60],[21],[271,208,272,273,274,275],{"trials":518,"activeCount":67},[],{"intervention":520,"totalTrials":31,"cells":521},"Sofosbuvir\u002FVelpatasvir",{"EARLY_PHASE1":522,"PHASE1":524,"PHASE2":526,"PHASE3":528,"PHASE4":530,"NA":543},{"trials":523,"activeCount":67},[],{"trials":525,"activeCount":67},[],{"trials":527,"activeCount":67},[],{"trials":529,"activeCount":67},[],{"trials":531,"activeCount":67},[532],{"nctId":533,"briefTitle":534,"status":220,"phases":535,"primaryCompletion":536,"completion":537,"start":538,"enrollment":539,"conditions":540,"interventions":542},"NCT03512210","Monitoring SOF\u002FVEL in Treatment Naïve, HCV Participants With Active Infection",[60],"2020-07-30","2021-02-28","2018-10-22",400,[27,25,541],"Liver Diseases",[520],{"trials":544,"activeCount":67},[],{"intervention":546,"totalTrials":31,"cells":547},"Etonogestrel (ENG) Subdermal Implants",{"EARLY_PHASE1":548,"PHASE1":550,"PHASE2":552,"PHASE3":554,"PHASE4":556,"NA":567},{"trials":549,"activeCount":67},[],{"trials":551,"activeCount":67},[],{"trials":553,"activeCount":67},[],{"trials":555,"activeCount":67},[],{"trials":557,"activeCount":67},[558],{"nctId":559,"briefTitle":560,"status":561,"phases":562,"primaryCompletion":563,"completion":563,"start":564,"enrollment":67,"conditions":565,"interventions":566},"NCT05156658","Pharmacokinetic Interactions of ENG Subdermal Implants with Long-Acting Cabotegravir (CAB-LA) and LA Rilpivirine (RPV-LA) (CARLA)","WITHDRAWN",[60],"2024-08-02","2024-01-01",[25],[546],{"trials":568,"activeCount":67},[],{"intervention":570,"totalTrials":31,"cells":571},"Doravirine 100 Mg",{"EARLY_PHASE1":572,"PHASE1":574,"PHASE2":576,"PHASE3":578,"PHASE4":580,"NA":594},{"trials":573,"activeCount":67},[],{"trials":575,"activeCount":67},[],{"trials":577,"activeCount":67},[],{"trials":579,"activeCount":67},[],{"trials":581,"activeCount":67},[582],{"nctId":583,"briefTitle":584,"status":220,"phases":585,"primaryCompletion":586,"completion":586,"start":587,"enrollment":588,"conditions":589,"interventions":590},"NCT04636437","Doravirine for Obese Persons on Integrase Inhibitors and Tenofovir Alafenamide",[60],"2024-10-18","2021-07-27",147,[18],[570,591,592,593],"Integrase strand transfer inhibitors","Tenofovir alafenamide\u002Femtricitabine","tenofovir disproxil fumarate\u002Femtricitabine",{"trials":595,"activeCount":67},[],{"intervention":591,"totalTrials":31,"cells":597},{"EARLY_PHASE1":598,"PHASE1":600,"PHASE2":602,"PHASE3":604,"PHASE4":606,"NA":612},{"trials":599,"activeCount":67},[],{"trials":601,"activeCount":67},[],{"trials":603,"activeCount":67},[],{"trials":605,"activeCount":67},[],{"trials":607,"activeCount":67},[608],{"nctId":583,"briefTitle":584,"status":220,"phases":609,"primaryCompletion":586,"completion":586,"start":587,"enrollment":588,"conditions":610,"interventions":611},[60],[18],[570,591,592,593],{"trials":613,"activeCount":67},[],{"intervention":592,"totalTrials":31,"cells":615},{"EARLY_PHASE1":616,"PHASE1":618,"PHASE2":620,"PHASE3":622,"PHASE4":624,"NA":630},{"trials":617,"activeCount":67},[],{"trials":619,"activeCount":67},[],{"trials":621,"activeCount":67},[],{"trials":623,"activeCount":67},[],{"trials":625,"activeCount":67},[626],{"nctId":583,"briefTitle":584,"status":220,"phases":627,"primaryCompletion":586,"completion":586,"start":587,"enrollment":588,"conditions":628,"interventions":629},[60],[18],[570,591,592,593],{"trials":631,"activeCount":67},[],{"intervention":593,"totalTrials":31,"cells":633},{"EARLY_PHASE1":634,"PHASE1":636,"PHASE2":638,"PHASE3":640,"PHASE4":642,"NA":648},{"trials":635,"activeCount":67},[],{"trials":637,"activeCount":67},[],{"trials":639,"activeCount":67},[],{"trials":641,"activeCount":67},[],{"trials":643,"activeCount":67},[644],{"nctId":583,"briefTitle":584,"status":220,"phases":645,"primaryCompletion":586,"completion":586,"start":587,"enrollment":588,"conditions":646,"interventions":647},[60],[18],[570,591,592,593],{"trials":649,"activeCount":67},[],{"intervention":285,"totalTrials":31,"cells":651},{"EARLY_PHASE1":652,"PHASE1":654,"PHASE2":656,"PHASE3":658,"PHASE4":660,"NA":666},{"trials":653,"activeCount":67},[],{"trials":655,"activeCount":67},[],{"trials":657,"activeCount":67},[],{"trials":659,"activeCount":67},[],{"trials":661,"activeCount":67},[662],{"nctId":277,"briefTitle":278,"status":220,"phases":663,"primaryCompletion":280,"completion":280,"start":281,"enrollment":282,"conditions":664,"interventions":665},[60],[18],[244,285,208,286,245,287],{"trials":667,"activeCount":67},[],{"intervention":669,"totalTrials":31,"cells":670},"Emtricitabine\u002Frilpivirine\u002Ftenofovir disoproxil fumarate",{"EARLY_PHASE1":671,"PHASE1":673,"PHASE2":675,"PHASE3":677,"PHASE4":679,"NA":691},{"trials":672,"activeCount":67},[],{"trials":674,"activeCount":67},[],{"trials":676,"activeCount":67},[],{"trials":678,"activeCount":67},[],{"trials":680,"activeCount":67},[681],{"nctId":682,"briefTitle":683,"status":220,"phases":684,"primaryCompletion":685,"completion":686,"start":687,"enrollment":688,"conditions":689,"interventions":690},"NCT01777997","FTC\u002FRPV\u002FTDF on T-Cell Activation, CD4+ T-Cell Count, Inflammatory Biomarkers and Viral Reservoir",[60],"2016-02-19","2017-02-07","2013-04-25",38,[15],[669],{"trials":692,"activeCount":67},[],{"intervention":694,"totalTrials":28,"cells":695},"efavirenz\u002Femtricitabine\u002Ftenofovir disoproxil fumarate",{"EARLY_PHASE1":696,"PHASE1":698,"PHASE2":700,"PHASE3":713,"PHASE4":727,"NA":729},{"trials":697,"activeCount":67},[],{"trials":699,"activeCount":67},[],{"trials":701,"activeCount":67},[702],{"nctId":703,"briefTitle":704,"status":561,"phases":705,"primaryCompletion":706,"completion":707,"start":708,"enrollment":67,"conditions":709,"interventions":710},"NCT01515813","Effect of HAART Vs. Statin Treatment on Endothelial Function and Inflammation\u002FCoagulation",[58],"2014-07","2014-12","2011-11",[15],[711,712,711],"Pravastatin sodium","Efavirenz\u002FEmtricitabine\u002FTenofovir Disoproxil Fumarate",{"trials":714,"activeCount":67},[715],{"nctId":716,"briefTitle":717,"status":220,"phases":718,"primaryCompletion":719,"completion":720,"start":721,"enrollment":722,"conditions":723,"interventions":725},"NCT01352117","Antiretroviral Therapy (ART) Alone or With Delayed Chemo Versus ART With Immediate Chemo for Limited AIDS-related Kaposi's Sarcoma",[59],"2016-03-16","2018-11-29","2011-11-18",192,[15,724],"Kaposi's Sarcoma",[694,726],"etoposide",{"trials":728,"activeCount":67},[],{"trials":730,"activeCount":67},[],{"intervention":726,"totalTrials":28,"cells":732},{"EARLY_PHASE1":733,"PHASE1":735,"PHASE2":737,"PHASE3":739,"PHASE4":759,"NA":761},{"trials":734,"activeCount":67},[],{"trials":736,"activeCount":67},[],{"trials":738,"activeCount":67},[],{"trials":740,"activeCount":67},[741,745],{"nctId":716,"briefTitle":717,"status":220,"phases":742,"primaryCompletion":719,"completion":720,"start":721,"enrollment":722,"conditions":743,"interventions":744},[59],[15,724],[694,726],{"nctId":746,"briefTitle":747,"status":220,"phases":748,"primaryCompletion":749,"completion":750,"start":751,"enrollment":752,"conditions":753,"interventions":754},"NCT01435018","Three Chemo Regimens as an Adjunct to ART for Treatment of Advanced AIDS-KS",[59],"2018-03-13","2019-08-29","2013-10-01",334,[15],[755,756,757,758],"Etoposide","Bleomycin and Vincristine","Paclitaxel","Co-formulated Efavirenz\u002FEmtricitabine\u002FTenofovir Disoproxil Fumarate",{"trials":760,"activeCount":67},[],{"trials":762,"activeCount":67},[],{"intervention":230,"totalTrials":28,"cells":764},{"EARLY_PHASE1":765,"PHASE1":767,"PHASE2":769,"PHASE3":775,"PHASE4":789,"NA":791},{"trials":766,"activeCount":67},[],{"trials":768,"activeCount":67},[],{"trials":770,"activeCount":67},[771],{"nctId":218,"briefTitle":219,"status":220,"phases":772,"primaryCompletion":222,"completion":222,"start":223,"enrollment":224,"conditions":773,"interventions":774},[57,58],[15,226],[228,229,208,230,231],{"trials":776,"activeCount":67},[777],{"nctId":778,"briefTitle":779,"status":220,"phases":780,"primaryCompletion":781,"completion":782,"start":783,"enrollment":784,"conditions":785,"interventions":786},"NCT00089505","NNRTI vs PI Regimens for HIV Infected Women After They Have Taken Nevirapine to Prevent Mother-To-Child HIV Transmission",[59],"2010-08","2011-02","2006-11",745,[18],[286,245,787,230,788],"Lopinavir\u002FRitonavir","Tenofovir disoproxil fumarate",{"trials":790,"activeCount":67},[],{"trials":792,"activeCount":67},[],{"intervention":370,"totalTrials":28,"cells":794},{"EARLY_PHASE1":795,"PHASE1":797,"PHASE2":799,"PHASE3":801,"PHASE4":811,"NA":813},{"trials":796,"activeCount":67},[],{"trials":798,"activeCount":67},[],{"trials":800,"activeCount":67},[],{"trials":802,"activeCount":67},[803,807],{"nctId":361,"briefTitle":362,"status":220,"phases":804,"primaryCompletion":364,"completion":364,"start":365,"enrollment":366,"conditions":805,"interventions":806},[59],[15],[228,228,336,229,369,370,371,372,373,374],{"nctId":235,"briefTitle":236,"status":220,"phases":808,"primaryCompletion":238,"completion":238,"start":239,"enrollment":240,"conditions":809,"interventions":810},[59],[18],[243,244,208,245,246,247,248],{"trials":812,"activeCount":67},[],{"trials":814,"activeCount":67},[],{"intervention":374,"totalTrials":28,"cells":816},{"EARLY_PHASE1":817,"PHASE1":819,"PHASE2":821,"PHASE3":834,"PHASE4":840,"NA":842},{"trials":818,"activeCount":67},[],{"trials":820,"activeCount":67},[],{"trials":822,"activeCount":67},[823],{"nctId":824,"briefTitle":825,"status":220,"phases":826,"primaryCompletion":827,"completion":828,"start":829,"enrollment":830,"conditions":831,"interventions":832},"NCT02582684","Dolutegravir Plus Lamivudine Dual Therapy in Treatment Naïve HIV-1 Patients",[58],"2017-02-28","2017-09-26","2015-12-08",122,[15],[833,374],"Dolutegravir",{"trials":835,"activeCount":67},[836],{"nctId":361,"briefTitle":362,"status":220,"phases":837,"primaryCompletion":364,"completion":364,"start":365,"enrollment":366,"conditions":838,"interventions":839},[59],[15],[228,228,336,229,369,370,371,372,373,374],{"trials":841,"activeCount":67},[],{"trials":843,"activeCount":67},[],{"intervention":756,"totalTrials":31,"cells":845},{"EARLY_PHASE1":846,"PHASE1":848,"PHASE2":850,"PHASE3":852,"PHASE4":858,"NA":860},{"trials":847,"activeCount":67},[],{"trials":849,"activeCount":67},[],{"trials":851,"activeCount":67},[],{"trials":853,"activeCount":67},[854],{"nctId":746,"briefTitle":747,"status":220,"phases":855,"primaryCompletion":749,"completion":750,"start":751,"enrollment":752,"conditions":856,"interventions":857},[59],[15],[755,756,757,758],{"trials":859,"activeCount":67},[],{"trials":861,"activeCount":67},[],{"intervention":757,"totalTrials":31,"cells":863},{"EARLY_PHASE1":864,"PHASE1":866,"PHASE2":868,"PHASE3":870,"PHASE4":876,"NA":878},{"trials":865,"activeCount":67},[],{"trials":867,"activeCount":67},[],{"trials":869,"activeCount":67},[],{"trials":871,"activeCount":67},[872],{"nctId":746,"briefTitle":747,"status":220,"phases":873,"primaryCompletion":749,"completion":750,"start":751,"enrollment":752,"conditions":874,"interventions":875},[59],[15],[755,756,757,758],{"trials":877,"activeCount":67},[],{"trials":879,"activeCount":67},[],{"intervention":758,"totalTrials":31,"cells":881},{"EARLY_PHASE1":882,"PHASE1":884,"PHASE2":886,"PHASE3":888,"PHASE4":894,"NA":896},{"trials":883,"activeCount":67},[],{"trials":885,"activeCount":67},[],{"trials":887,"activeCount":67},[],{"trials":889,"activeCount":67},[890],{"nctId":746,"briefTitle":747,"status":220,"phases":891,"primaryCompletion":749,"completion":750,"start":751,"enrollment":752,"conditions":892,"interventions":893},[59],[15],[755,756,757,758],{"trials":895,"activeCount":67},[],{"trials":897,"activeCount":67},[],{"intervention":899,"totalTrials":31,"cells":900},"Pitavastatin",{"EARLY_PHASE1":901,"PHASE1":903,"PHASE2":905,"PHASE3":907,"PHASE4":919,"NA":921},{"trials":902,"activeCount":67},[],{"trials":904,"activeCount":67},[],{"trials":906,"activeCount":67},[],{"trials":908,"activeCount":67},[909],{"nctId":910,"briefTitle":911,"status":220,"phases":912,"primaryCompletion":913,"completion":913,"start":914,"enrollment":915,"conditions":916,"interventions":917},"NCT03070223","PREPARE (A5361s) Ancillary Study of REPRIEVE (A5332)",[59],"2023-08-21","2017-03-14",602,[15],[899,918],"Placebos",{"trials":920,"activeCount":67},[],{"trials":922,"activeCount":67},[],{"intervention":918,"totalTrials":31,"cells":924},{"EARLY_PHASE1":925,"PHASE1":927,"PHASE2":929,"PHASE3":931,"PHASE4":937,"NA":939},{"trials":926,"activeCount":67},[],{"trials":928,"activeCount":67},[],{"trials":930,"activeCount":67},[],{"trials":932,"activeCount":67},[933],{"nctId":910,"briefTitle":911,"status":220,"phases":934,"primaryCompletion":913,"completion":913,"start":914,"enrollment":915,"conditions":935,"interventions":936},[59],[15],[899,918],{"trials":938,"activeCount":67},[],{"trials":940,"activeCount":67},[],{"intervention":369,"totalTrials":31,"cells":942},{"EARLY_PHASE1":943,"PHASE1":945,"PHASE2":947,"PHASE3":949,"PHASE4":955,"NA":957},{"trials":944,"activeCount":67},[],{"trials":946,"activeCount":67},[],{"trials":948,"activeCount":67},[],{"trials":950,"activeCount":67},[951],{"nctId":361,"briefTitle":362,"status":220,"phases":952,"primaryCompletion":364,"completion":364,"start":365,"enrollment":366,"conditions":953,"interventions":954},[59],[15],[228,228,336,229,369,370,371,372,373,374],{"trials":956,"activeCount":67},[],{"trials":958,"activeCount":67},[],{"intervention":372,"totalTrials":31,"cells":960},{"EARLY_PHASE1":961,"PHASE1":963,"PHASE2":965,"PHASE3":967,"PHASE4":973,"NA":975},{"trials":962,"activeCount":67},[],{"trials":964,"activeCount":67},[],{"trials":966,"activeCount":67},[],{"trials":968,"activeCount":67},[969],{"nctId":361,"briefTitle":362,"status":220,"phases":970,"primaryCompletion":364,"completion":364,"start":365,"enrollment":366,"conditions":971,"interventions":972},[59],[15],[228,228,336,229,369,370,371,372,373,374],{"trials":974,"activeCount":67},[],{"trials":976,"activeCount":67},[],{"intervention":247,"totalTrials":31,"cells":978},{"EARLY_PHASE1":979,"PHASE1":981,"PHASE2":983,"PHASE3":985,"PHASE4":991,"NA":993},{"trials":980,"activeCount":67},[],{"trials":982,"activeCount":67},[],{"trials":984,"activeCount":67},[],{"trials":986,"activeCount":67},[987],{"nctId":235,"briefTitle":236,"status":220,"phases":988,"primaryCompletion":238,"completion":238,"start":239,"enrollment":240,"conditions":989,"interventions":990},[59],[18],[243,244,208,245,246,247,248],{"trials":992,"activeCount":67},[],{"trials":994,"activeCount":67},[],{"intervention":248,"totalTrials":31,"cells":996},{"EARLY_PHASE1":997,"PHASE1":999,"PHASE2":1001,"PHASE3":1003,"PHASE4":1009,"NA":1011},{"trials":998,"activeCount":67},[],{"trials":1000,"activeCount":67},[],{"trials":1002,"activeCount":67},[],{"trials":1004,"activeCount":67},[1005],{"nctId":235,"briefTitle":236,"status":220,"phases":1006,"primaryCompletion":238,"completion":238,"start":239,"enrollment":240,"conditions":1007,"interventions":1008},[59],[18],[243,244,208,245,246,247,248],{"trials":1010,"activeCount":67},[],{"trials":1012,"activeCount":67},[],{"intervention":1014,"totalTrials":31,"cells":1015},"Gentian Violet",{"EARLY_PHASE1":1016,"PHASE1":1018,"PHASE2":1020,"PHASE3":1022,"PHASE4":1035,"NA":1037},{"trials":1017,"activeCount":67},[],{"trials":1019,"activeCount":67},[],{"trials":1021,"activeCount":67},[],{"trials":1023,"activeCount":67},[1024],{"nctId":1025,"briefTitle":1026,"status":220,"phases":1027,"primaryCompletion":1028,"completion":1029,"start":1030,"enrollment":1031,"conditions":1032,"interventions":1033},"NCT01427738","Gentian Violet Vs. Nystatin Oral Suspension for Treatment of Oropharyngeal Candidiasis",[59],"2012-09","2014-01","2011-06",221,[15],[1014,1034],"Nystatin oral suspension",{"trials":1036,"activeCount":67},[],{"trials":1038,"activeCount":67},[],{"intervention":1034,"totalTrials":31,"cells":1040},{"EARLY_PHASE1":1041,"PHASE1":1043,"PHASE2":1045,"PHASE3":1047,"PHASE4":1053,"NA":1055},{"trials":1042,"activeCount":67},[],{"trials":1044,"activeCount":67},[],{"trials":1046,"activeCount":67},[],{"trials":1048,"activeCount":67},[1049],{"nctId":1025,"briefTitle":1026,"status":220,"phases":1050,"primaryCompletion":1028,"completion":1029,"start":1030,"enrollment":1031,"conditions":1051,"interventions":1052},[59],[15],[1014,1034],{"trials":1054,"activeCount":67},[],{"trials":1056,"activeCount":67},[],{"intervention":1058,"totalTrials":1059,"cells":1060},"Ribavirin",3,{"EARLY_PHASE1":1061,"PHASE1":1063,"PHASE2":1076,"PHASE3":1102,"PHASE4":1104,"NA":1106},{"trials":1062,"activeCount":67},[],{"trials":1064,"activeCount":67},[1065],{"nctId":1066,"briefTitle":1067,"status":220,"phases":1068,"primaryCompletion":827,"completion":1069,"start":1070,"enrollment":1071,"conditions":1072,"interventions":1073},"NCT02128217","Sofosbuvir-Containing Regimens Without Interferon For Treatment of Acute Hepatitis C Virus (HCV) Infection",[57],"2017-05-09","2014-05-30",44,[15,33],[1074,1058,1075],"Sofosbuvir","Ledipasvir\u002FSofosbuvir",{"trials":1077,"activeCount":67},[1078,1088],{"nctId":1079,"briefTitle":1080,"status":326,"phases":1081,"primaryCompletion":1082,"completion":1083,"start":1084,"enrollment":11,"conditions":1085,"interventions":1086},"NCT02605304","12 Weeks of Ledipasvir (LDV)\u002FSofosbuvir (SOF) With Weight-based Ribavirin vs. 24 Weeks of LDV\u002FSOF",[58],"2017-01-20","2017-03-20","2016-02-17",[15,27],[1087,1058],"Ledipasvir\u002Fsofosbuvir",{"nctId":1089,"briefTitle":1090,"status":220,"phases":1091,"primaryCompletion":1092,"completion":1093,"start":1094,"enrollment":1095,"conditions":1096,"interventions":1098},"NCT00665353","Pioglitazone Before Peginterferon and Ribavirin for Hepatitis C Infection in HIV\u002FHCV-Coinfected Patients With Insulin Resistance",[58],"2011-05","2011-12","2009-03",19,[1097],"HIV-1 and Hepatitis C Co-Infection",[1099,1100,1101],"pioglitazone","peginterferon","ribavirin",{"trials":1103,"activeCount":67},[],{"trials":1105,"activeCount":67},[],{"trials":1107,"activeCount":67},[],{"intervention":1075,"totalTrials":28,"cells":1109},{"EARLY_PHASE1":1110,"PHASE1":1112,"PHASE2":1118,"PHASE3":1124,"PHASE4":1126,"NA":1128},{"trials":1111,"activeCount":67},[],{"trials":1113,"activeCount":67},[1114],{"nctId":1066,"briefTitle":1067,"status":220,"phases":1115,"primaryCompletion":827,"completion":1069,"start":1070,"enrollment":1071,"conditions":1116,"interventions":1117},[57],[15,33],[1074,1058,1075],{"trials":1119,"activeCount":67},[1120],{"nctId":1079,"briefTitle":1080,"status":326,"phases":1121,"primaryCompletion":1082,"completion":1083,"start":1084,"enrollment":11,"conditions":1122,"interventions":1123},[58],[15,27],[1087,1058],{"trials":1125,"activeCount":67},[],{"trials":1127,"activeCount":67},[],{"trials":1129,"activeCount":67},[],{"intervention":1131,"totalTrials":28,"cells":1132},"Aspirin",{"EARLY_PHASE1":1133,"PHASE1":1135,"PHASE2":1137,"PHASE3":1159,"PHASE4":1161,"NA":1163},{"trials":1134,"activeCount":67},[],{"trials":1136,"activeCount":67},[],{"trials":1138,"activeCount":67},[1139,1149],{"nctId":1140,"briefTitle":1141,"status":220,"phases":1142,"primaryCompletion":1143,"completion":1144,"start":1145,"enrollment":1146,"conditions":1147,"interventions":1148},"NCT02155985","Modulation of Immune Activation by Aspirin",[58],"2015-06","2015-07","2014-08",121,[15],[1131],{"nctId":1150,"briefTitle":1151,"status":220,"phases":1152,"primaryCompletion":1153,"completion":1153,"start":708,"enrollment":1154,"conditions":1155,"interventions":1156},"NCT01426438","Endothelial Function, Lipoproteins, and Inflammation With Low HDL Cholesterol in HIV: ER Niacin Versus Fenofibrate",[58],"2013-10",99,[15],[1157,1131,1158],"Niacin","Fenofibrate",{"trials":1160,"activeCount":67},[],{"trials":1162,"activeCount":67},[],{"trials":1164,"activeCount":67},[],{"intervention":310,"totalTrials":28,"cells":1166},{"EARLY_PHASE1":1167,"PHASE1":1169,"PHASE2":1171,"PHASE3":1181,"PHASE4":1183,"NA":1185},{"trials":1168,"activeCount":67},[],{"trials":1170,"activeCount":67},[],{"trials":1172,"activeCount":67},[1173,1177],{"nctId":300,"briefTitle":301,"status":220,"phases":1174,"primaryCompletion":303,"completion":304,"start":305,"enrollment":306,"conditions":1175,"interventions":1176},[58],[23],[309,275,310,311,312],{"nctId":324,"briefTitle":325,"status":326,"phases":1178,"primaryCompletion":328,"completion":329,"start":330,"enrollment":331,"conditions":1179,"interventions":1180},[58],[21,23],[334,335,336,275,337,310,311,338,339],{"trials":1182,"activeCount":67},[],{"trials":1184,"activeCount":67},[],{"trials":1186,"activeCount":67},[],{"intervention":311,"totalTrials":28,"cells":1188},{"EARLY_PHASE1":1189,"PHASE1":1191,"PHASE2":1193,"PHASE3":1203,"PHASE4":1205,"NA":1207},{"trials":1190,"activeCount":67},[],{"trials":1192,"activeCount":67},[],{"trials":1194,"activeCount":67},[1195,1199],{"nctId":300,"briefTitle":301,"status":220,"phases":1196,"primaryCompletion":303,"completion":304,"start":305,"enrollment":306,"conditions":1197,"interventions":1198},[58],[23],[309,275,310,311,312],{"nctId":324,"briefTitle":325,"status":326,"phases":1200,"primaryCompletion":328,"completion":329,"start":330,"enrollment":331,"conditions":1201,"interventions":1202},[58],[21,23],[334,335,336,275,337,310,311,338,339],{"trials":1204,"activeCount":67},[],{"trials":1206,"activeCount":67},[],{"trials":1208,"activeCount":67},[],{"intervention":1210,"totalTrials":31,"cells":1211},"Sevelamer carbonate",{"EARLY_PHASE1":1212,"PHASE1":1214,"PHASE2":1216,"PHASE3":1226,"PHASE4":1228,"NA":1230},{"trials":1213,"activeCount":67},[],{"trials":1215,"activeCount":67},[],{"trials":1217,"activeCount":67},[1218],{"nctId":1219,"briefTitle":1220,"status":220,"phases":1221,"primaryCompletion":1028,"completion":1222,"start":708,"enrollment":1223,"conditions":1224,"interventions":1225},"NCT01543958","Sevelamer for Reducing Endotoxemia and Immune Activation",[58],"2012-11",40,[15],[1210],{"trials":1227,"activeCount":67},[],{"trials":1229,"activeCount":67},[],{"trials":1231,"activeCount":67},[],{"intervention":1233,"totalTrials":31,"cells":1234},"Sitagliptin",{"EARLY_PHASE1":1235,"PHASE1":1237,"PHASE2":1239,"PHASE3":1251,"PHASE4":1253,"NA":1255},{"trials":1236,"activeCount":67},[],{"trials":1238,"activeCount":67},[],{"trials":1240,"activeCount":67},[1241],{"nctId":1242,"briefTitle":1243,"status":220,"phases":1244,"primaryCompletion":1245,"completion":1246,"start":1247,"enrollment":1248,"conditions":1249,"interventions":1250},"NCT02513771","Sitagliptin for Reducing Inflammation and Immune Activation",[58],"2016-12-13","2017-01-10","2015-09",90,[15],[1233],{"trials":1252,"activeCount":67},[],{"trials":1254,"activeCount":67},[],{"trials":1256,"activeCount":67},[],{"intervention":1258,"totalTrials":31,"cells":1259},"Emtricitabine\u002F tenofovir disoproxil fumarate",{"EARLY_PHASE1":1260,"PHASE1":1262,"PHASE2":1264,"PHASE3":1275,"PHASE4":1277,"NA":1279},{"trials":1261,"activeCount":67},[],{"trials":1263,"activeCount":67},[],{"trials":1265,"activeCount":67},[1266],{"nctId":1267,"briefTitle":1268,"status":326,"phases":1269,"primaryCompletion":1270,"completion":1092,"start":1271,"enrollment":1272,"conditions":1273,"interventions":1274},"NCT00090779","Nine Month Course of Anti-HIV Medications for People Recently Infected With HIV",[58],"2009-07","2005-01",130,[18],[1258,787],{"trials":1276,"activeCount":67},[],{"trials":1278,"activeCount":67},[],{"trials":1280,"activeCount":67},[],{"intervention":1282,"totalTrials":31,"cells":1283},"Rifaximin",{"EARLY_PHASE1":1284,"PHASE1":1286,"PHASE2":1288,"PHASE3":1298,"PHASE4":1300,"NA":1302},{"trials":1285,"activeCount":67},[],{"trials":1287,"activeCount":67},[],{"trials":1289,"activeCount":67},[1290],{"nctId":1291,"briefTitle":1292,"status":220,"phases":1293,"primaryCompletion":1028,"completion":1222,"start":1294,"enrollment":1295,"conditions":1296,"interventions":1297},"NCT01466595","Rifaximin as a Modulator of Microbial Translocation and Immune Activation",[58],"2011-09",73,[15],[1282],{"trials":1299,"activeCount":67},[],{"trials":1301,"activeCount":67},[],{"trials":1303,"activeCount":67},[],{"intervention":1305,"totalTrials":31,"cells":1306},"Minocycline",{"EARLY_PHASE1":1307,"PHASE1":1309,"PHASE2":1311,"PHASE3":1322,"PHASE4":1324,"NA":1326},{"trials":1308,"activeCount":67},[],{"trials":1310,"activeCount":67},[],{"trials":1312,"activeCount":67},[1313],{"nctId":1314,"briefTitle":1315,"status":326,"phases":1316,"primaryCompletion":1317,"completion":1317,"start":1318,"enrollment":1319,"conditions":1320,"interventions":1321},"NCT00361257","Minocycline for the Treatment of Decreased Mental Function in HIV-Infected Adults",[58],"2010-01","2007-03",107,[18],[1305],{"trials":1323,"activeCount":67},[],{"trials":1325,"activeCount":67},[],{"trials":1327,"activeCount":67},[],{"intervention":1329,"totalTrials":31,"cells":1330},"Visbiome Extra Strength",{"EARLY_PHASE1":1331,"PHASE1":1333,"PHASE2":1335,"PHASE3":1346,"PHASE4":1348,"NA":1350},{"trials":1332,"activeCount":67},[],{"trials":1334,"activeCount":67},[],{"trials":1336,"activeCount":67},[1337],{"nctId":1338,"briefTitle":1339,"status":220,"phases":1340,"primaryCompletion":1341,"completion":1342,"start":266,"enrollment":1343,"conditions":1344,"interventions":1345},"NCT02706717","Effects of the Probiotic Visbiome Extra Strength on Gut Microbiome & Immune Activation Markers",[58],"2017-06-05","2017-08-28",93,[15],[1329],{"trials":1347,"activeCount":67},[],{"trials":1349,"activeCount":67},[],{"trials":1351,"activeCount":67},[],{"intervention":1353,"totalTrials":31,"cells":1354},"Glecaprevir\u002FPibrentasvir",{"EARLY_PHASE1":1355,"PHASE1":1357,"PHASE2":1359,"PHASE3":1372,"PHASE4":1374,"NA":1376},{"trials":1356,"activeCount":67},[],{"trials":1358,"activeCount":67},[],{"trials":1360,"activeCount":67},[1361],{"nctId":1362,"briefTitle":1363,"status":220,"phases":1364,"primaryCompletion":1365,"completion":1366,"start":1367,"enrollment":1368,"conditions":1369,"interventions":1371},"NCT04042740","Glecaprevir\u002FPibrentasvir Fixed-dose Combination Treatment for Acute Hepatitis C Virus Infection",[58],"2023-05-18","2023-08-22","2019-11-20",45,[1370,21],"Hepatitis C Infection",[1353],{"trials":1373,"activeCount":67},[],{"trials":1375,"activeCount":67},[],{"trials":1377,"activeCount":67},[],{"intervention":1379,"totalTrials":31,"cells":1380},"Isotretinoin",{"EARLY_PHASE1":1381,"PHASE1":1383,"PHASE2":1385,"PHASE3":1397,"PHASE4":1399,"NA":1401},{"trials":1382,"activeCount":67},[],{"trials":1384,"activeCount":67},[],{"trials":1386,"activeCount":67},[1387],{"nctId":1388,"briefTitle":1389,"status":220,"phases":1390,"primaryCompletion":1391,"completion":1392,"start":1393,"enrollment":1394,"conditions":1395,"interventions":1396},"NCT01969058","Effect of Isotretinoin on Immune Activation Among HIV-1 Infected Subjects With Incomplete CD4+ T Cell Recovery",[58],"2016-08-31","2016-11","2014-07-02",76,[15],[1379],{"trials":1398,"activeCount":67},[],{"trials":1400,"activeCount":67},[],{"trials":1402,"activeCount":67},[],{"intervention":1099,"totalTrials":31,"cells":1404},{"EARLY_PHASE1":1405,"PHASE1":1407,"PHASE2":1409,"PHASE3":1415,"PHASE4":1417,"NA":1419},{"trials":1406,"activeCount":67},[],{"trials":1408,"activeCount":67},[],{"trials":1410,"activeCount":67},[1411],{"nctId":1089,"briefTitle":1090,"status":220,"phases":1412,"primaryCompletion":1092,"completion":1093,"start":1094,"enrollment":1095,"conditions":1413,"interventions":1414},[58],[1097],[1099,1100,1101],{"trials":1416,"activeCount":67},[],{"trials":1418,"activeCount":67},[],{"trials":1420,"activeCount":67},[],{"intervention":1100,"totalTrials":31,"cells":1422},{"EARLY_PHASE1":1423,"PHASE1":1425,"PHASE2":1427,"PHASE3":1433,"PHASE4":1435,"NA":1437},{"trials":1424,"activeCount":67},[],{"trials":1426,"activeCount":67},[],{"trials":1428,"activeCount":67},[1429],{"nctId":1089,"briefTitle":1090,"status":220,"phases":1430,"primaryCompletion":1092,"completion":1093,"start":1094,"enrollment":1095,"conditions":1431,"interventions":1432},[58],[1097],[1099,1100,1101],{"trials":1434,"activeCount":67},[],{"trials":1436,"activeCount":67},[],{"trials":1438,"activeCount":67},[],{"intervention":1440,"totalTrials":31,"cells":1441},"EFV",{"EARLY_PHASE1":1442,"PHASE1":1444,"PHASE2":1446,"PHASE3":1461,"PHASE4":1463,"NA":1465},{"trials":1443,"activeCount":67},[],{"trials":1445,"activeCount":67},[],{"trials":1447,"activeCount":67},[1448],{"nctId":1449,"briefTitle":1450,"status":220,"phases":1451,"primaryCompletion":1452,"completion":1453,"start":1454,"enrollment":1455,"conditions":1456,"interventions":1457},"NCT01903031","Evaluating Pharmacokinetic Interactions With Vaginal Ring Contraceptives and ART",[58],"2016-10-03","2016-10-10","2014-12-30",84,[15],[1440,1458,1459,1460],"ATV\u002Fr","TDF","NRTIs",{"trials":1462,"activeCount":67},[],{"trials":1464,"activeCount":67},[],{"trials":1466,"activeCount":67},[],{"intervention":1458,"totalTrials":31,"cells":1468},{"EARLY_PHASE1":1469,"PHASE1":1471,"PHASE2":1473,"PHASE3":1479,"PHASE4":1481,"NA":1483},{"trials":1470,"activeCount":67},[],{"trials":1472,"activeCount":67},[],{"trials":1474,"activeCount":67},[1475],{"nctId":1449,"briefTitle":1450,"status":220,"phases":1476,"primaryCompletion":1452,"completion":1453,"start":1454,"enrollment":1455,"conditions":1477,"interventions":1478},[58],[15],[1440,1458,1459,1460],{"trials":1480,"activeCount":67},[],{"trials":1482,"activeCount":67},[],{"trials":1484,"activeCount":67},[],{"intervention":1459,"totalTrials":31,"cells":1486},{"EARLY_PHASE1":1487,"PHASE1":1489,"PHASE2":1491,"PHASE3":1497,"PHASE4":1499,"NA":1501},{"trials":1488,"activeCount":67},[],{"trials":1490,"activeCount":67},[],{"trials":1492,"activeCount":67},[1493],{"nctId":1449,"briefTitle":1450,"status":220,"phases":1494,"primaryCompletion":1452,"completion":1453,"start":1454,"enrollment":1455,"conditions":1495,"interventions":1496},[58],[15],[1440,1458,1459,1460],{"trials":1498,"activeCount":67},[],{"trials":1500,"activeCount":67},[],{"trials":1502,"activeCount":67},[],{"intervention":1460,"totalTrials":31,"cells":1504},{"EARLY_PHASE1":1505,"PHASE1":1507,"PHASE2":1509,"PHASE3":1515,"PHASE4":1517,"NA":1519},{"trials":1506,"activeCount":67},[],{"trials":1508,"activeCount":67},[],{"trials":1510,"activeCount":67},[1511],{"nctId":1449,"briefTitle":1450,"status":220,"phases":1512,"primaryCompletion":1452,"completion":1453,"start":1454,"enrollment":1455,"conditions":1513,"interventions":1514},[58],[15],[1440,1458,1459,1460],{"trials":1516,"activeCount":67},[],{"trials":1518,"activeCount":67},[],{"trials":1520,"activeCount":67},[],{"intervention":309,"totalTrials":31,"cells":1522},{"EARLY_PHASE1":1523,"PHASE1":1525,"PHASE2":1527,"PHASE3":1533,"PHASE4":1535,"NA":1537},{"trials":1524,"activeCount":67},[],{"trials":1526,"activeCount":67},[],{"trials":1528,"activeCount":67},[1529],{"nctId":300,"briefTitle":301,"status":220,"phases":1530,"primaryCompletion":303,"completion":304,"start":305,"enrollment":306,"conditions":1531,"interventions":1532},[58],[23],[309,275,310,311,312],{"trials":1534,"activeCount":67},[],{"trials":1536,"activeCount":67},[],{"trials":1538,"activeCount":67},[],{"intervention":312,"totalTrials":31,"cells":1540},{"EARLY_PHASE1":1541,"PHASE1":1543,"PHASE2":1545,"PHASE3":1551,"PHASE4":1553,"NA":1555},{"trials":1542,"activeCount":67},[],{"trials":1544,"activeCount":67},[],{"trials":1546,"activeCount":67},[1547],{"nctId":300,"briefTitle":301,"status":220,"phases":1548,"primaryCompletion":303,"completion":304,"start":305,"enrollment":306,"conditions":1549,"interventions":1550},[58],[23],[309,275,310,311,312],{"trials":1552,"activeCount":67},[],{"trials":1554,"activeCount":67},[],{"trials":1556,"activeCount":67},[],{"intervention":1558,"totalTrials":31,"cells":1559},"Darunavir\u002FRitonavir",{"EARLY_PHASE1":1560,"PHASE1":1562,"PHASE2":1564,"PHASE3":1577,"PHASE4":1579,"NA":1581},{"trials":1561,"activeCount":67},[],{"trials":1563,"activeCount":67},[],{"trials":1565,"activeCount":67},[1566],{"nctId":1567,"briefTitle":1568,"status":220,"phases":1569,"primaryCompletion":1570,"completion":1571,"start":1572,"enrollment":1573,"conditions":1574,"interventions":1576},"NCT00830804","Safety and Effectiveness of Raltegravir Plus Darunavir\u002FRitonavir in Treatment-Naive HIV-Infected Adults",[58],"2010-02","2010-09","2009-04",113,[1575],"HIV-1 Infections",[336,1558],{"trials":1578,"activeCount":67},[],{"trials":1580,"activeCount":67},[],{"trials":1582,"activeCount":67},[],{"intervention":1584,"totalTrials":31,"cells":1585},"elvitegravir\u002Fcobicistat\u002Femtricitabine\u002Ftenofovir alafenamide or bictegravir\u002Femtricitabine\u002Ftenofovir alafenamide or other medically-appropriate FDA-approved antiretroviral therapy",{"EARLY_PHASE1":1586,"PHASE1":1588,"PHASE2":1590,"PHASE3":1602,"PHASE4":1604,"NA":1606},{"trials":1587,"activeCount":67},[],{"trials":1589,"activeCount":67},[],{"trials":1591,"activeCount":67},[1592],{"nctId":1593,"briefTitle":1594,"status":220,"phases":1595,"primaryCompletion":1596,"completion":1597,"start":1598,"enrollment":1599,"conditions":1600,"interventions":1601},"NCT02859558","Early ART to Limit Infection and Establishment of Reservoir",[58],"2020-12-02","2025-04-16","2017-01-24",195,[15],[1584],{"trials":1603,"activeCount":67},[],{"trials":1605,"activeCount":67},[],{"trials":1607,"activeCount":67},[],{"intervention":1609,"totalTrials":31,"cells":1610},"Chloroquine",{"EARLY_PHASE1":1611,"PHASE1":1613,"PHASE2":1615,"PHASE3":1625,"PHASE4":1627,"NA":1629},{"trials":1612,"activeCount":67},[],{"trials":1614,"activeCount":67},[],{"trials":1616,"activeCount":67},[1617],{"nctId":1618,"briefTitle":1619,"status":220,"phases":1620,"primaryCompletion":1621,"completion":1622,"start":1094,"enrollment":6,"conditions":1623,"interventions":1624},"NCT00819390","Chloroquine for Reducing Immune Activation in HIV- Infected Individuals",[58],"2013-02","2013-05",[18],[1609],{"trials":1626,"activeCount":67},[],{"trials":1628,"activeCount":67},[],{"trials":1630,"activeCount":67},[],{"intervention":1632,"totalTrials":31,"cells":1633},"Depot medroxyprogesterone acetate",{"EARLY_PHASE1":1634,"PHASE1":1636,"PHASE2":1638,"PHASE3":1649,"PHASE4":1651,"NA":1653},{"trials":1635,"activeCount":67},[],{"trials":1637,"activeCount":67},[],{"trials":1639,"activeCount":67},[1640],{"nctId":1641,"briefTitle":1642,"status":220,"phases":1643,"primaryCompletion":1644,"completion":1644,"start":1645,"enrollment":1646,"conditions":1647,"interventions":1648},"NCT02412436","PK Study of Rifampicin Interactions With DMPA and Efavirenz in TB",[58],"2017-06-15","2015-11-03",62,[15,23],[1632],{"trials":1650,"activeCount":67},[],{"trials":1652,"activeCount":67},[],{"trials":1654,"activeCount":67},[],{"intervention":1157,"totalTrials":31,"cells":1656},{"EARLY_PHASE1":1657,"PHASE1":1659,"PHASE2":1661,"PHASE3":1667,"PHASE4":1669,"NA":1671},{"trials":1658,"activeCount":67},[],{"trials":1660,"activeCount":67},[],{"trials":1662,"activeCount":67},[1663],{"nctId":1150,"briefTitle":1151,"status":220,"phases":1664,"primaryCompletion":1153,"completion":1153,"start":708,"enrollment":1154,"conditions":1665,"interventions":1666},[58],[15],[1157,1131,1158],{"trials":1668,"activeCount":67},[],{"trials":1670,"activeCount":67},[],{"trials":1672,"activeCount":67},[],{"intervention":1158,"totalTrials":31,"cells":1674},{"EARLY_PHASE1":1675,"PHASE1":1677,"PHASE2":1679,"PHASE3":1685,"PHASE4":1687,"NA":1689},{"trials":1676,"activeCount":67},[],{"trials":1678,"activeCount":67},[],{"trials":1680,"activeCount":67},[1681],{"nctId":1150,"briefTitle":1151,"status":220,"phases":1682,"primaryCompletion":1153,"completion":1153,"start":708,"enrollment":1154,"conditions":1683,"interventions":1684},[58],[15],[1157,1131,1158],{"trials":1686,"activeCount":67},[],{"trials":1688,"activeCount":67},[],{"trials":1690,"activeCount":67},[],{"intervention":1692,"totalTrials":31,"cells":1693},"Telmisartan",{"EARLY_PHASE1":1694,"PHASE1":1696,"PHASE2":1698,"PHASE3":1708,"PHASE4":1710,"NA":1712},{"trials":1695,"activeCount":67},[],{"trials":1697,"activeCount":67},[],{"trials":1699,"activeCount":67},[1700],{"nctId":1701,"briefTitle":1702,"status":220,"phases":1703,"primaryCompletion":1704,"completion":1704,"start":1029,"enrollment":1705,"conditions":1706,"interventions":1707},"NCT01928927","Telmisartan to Reduce AIDS-Related Fibrotic and Inflammatory Contributors (TRAFIC Study)",[58],"2016-03",58,[15],[1692],{"trials":1709,"activeCount":67},[],{"trials":1711,"activeCount":67},[],{"trials":1713,"activeCount":67},[],{"intervention":711,"totalTrials":31,"cells":1715},{"EARLY_PHASE1":1716,"PHASE1":1718,"PHASE2":1720,"PHASE3":1726,"PHASE4":1728,"NA":1730},{"trials":1717,"activeCount":67},[],{"trials":1719,"activeCount":67},[],{"trials":1721,"activeCount":67},[1722],{"nctId":703,"briefTitle":704,"status":561,"phases":1723,"primaryCompletion":706,"completion":707,"start":708,"enrollment":67,"conditions":1724,"interventions":1725},[58],[15],[711,712,711],{"trials":1727,"activeCount":67},[],{"trials":1729,"activeCount":67},[],{"trials":1731,"activeCount":67},[],{"intervention":1733,"totalTrials":31,"cells":1734},"Levonorgestrel",{"EARLY_PHASE1":1735,"PHASE1":1737,"PHASE2":1739,"PHASE3":1750,"PHASE4":1752,"NA":1754},{"trials":1736,"activeCount":67},[],{"trials":1738,"activeCount":67},[],{"trials":1740,"activeCount":67},[1741],{"nctId":1742,"briefTitle":1743,"status":220,"phases":1744,"primaryCompletion":1745,"completion":1746,"start":1747,"enrollment":830,"conditions":1748,"interventions":1749},"NCT03819114","Pharmacokinetic Study to Evaluate Double-Dose Levonorgestrel Emergency Contraception in Combination With Efavirenz-Based Antiretroviral Therapy or Rifampicin-Containing Anti-Tuberculosis Therapy",[58],"2020-11-02","2020-11-30","2019-05-06",[18,23],[1733],{"trials":1751,"activeCount":67},[],{"trials":1753,"activeCount":67},[],{"trials":1755,"activeCount":67},[],{"intervention":231,"totalTrials":31,"cells":1757},{"EARLY_PHASE1":1758,"PHASE1":1760,"PHASE2":1762,"PHASE3":1768,"PHASE4":1770,"NA":1772},{"trials":1759,"activeCount":67},[],{"trials":1761,"activeCount":67},[],{"trials":1763,"activeCount":67},[1764],{"nctId":218,"briefTitle":219,"status":220,"phases":1765,"primaryCompletion":222,"completion":222,"start":223,"enrollment":224,"conditions":1766,"interventions":1767},[57,58],[15,226],[228,229,208,230,231],{"trials":1769,"activeCount":67},[],{"trials":1771,"activeCount":67},[],{"trials":1773,"activeCount":67},[],{"intervention":1775,"totalTrials":31,"cells":1776},"atorvastatin",{"EARLY_PHASE1":1777,"PHASE1":1779,"PHASE2":1781,"PHASE3":1792,"PHASE4":1794,"NA":1796},{"trials":1778,"activeCount":67},[],{"trials":1780,"activeCount":67},[],{"trials":1782,"activeCount":67},[1783],{"nctId":1784,"briefTitle":1785,"status":220,"phases":1786,"primaryCompletion":1787,"completion":1787,"start":1788,"enrollment":1789,"conditions":1790,"interventions":1791},"NCT01351025","Atorvastatin on Biomarkers of Inflammation, Coagulopathy, Angiogenesis & T-cells",[58],"2014-05","2011-04-14",98,[15],[1775,1775],{"trials":1793,"activeCount":67},[],{"trials":1795,"activeCount":67},[],{"trials":1797,"activeCount":67},[],{"intervention":1799,"totalTrials":31,"cells":1800},"Sirolimus",{"EARLY_PHASE1":1801,"PHASE1":1803,"PHASE2":1805,"PHASE3":1816,"PHASE4":1818,"NA":1820},{"trials":1802,"activeCount":67},[],{"trials":1804,"activeCount":67},[],{"trials":1806,"activeCount":67},[1807],{"nctId":1808,"briefTitle":1809,"status":220,"phases":1810,"primaryCompletion":1811,"completion":1812,"start":1813,"enrollment":177,"conditions":1814,"interventions":1815},"NCT02440789","Safety and Efficacy of Sirolimus for HIV Reservoir Reduction in Individuals on Suppressive Antiretroviral Therapy (ART)",[57,58],"2017-11-02","2018-02-01","2015-12-21",[15],[1799],{"trials":1817,"activeCount":67},[],{"trials":1819,"activeCount":67},[],{"trials":1821,"activeCount":67},[],{"intervention":334,"totalTrials":31,"cells":1823},{"EARLY_PHASE1":1824,"PHASE1":1826,"PHASE2":1828,"PHASE3":1834,"PHASE4":1836,"NA":1838},{"trials":1825,"activeCount":67},[],{"trials":1827,"activeCount":67},[],{"trials":1829,"activeCount":67},[1830],{"nctId":324,"briefTitle":325,"status":326,"phases":1831,"primaryCompletion":328,"completion":329,"start":330,"enrollment":331,"conditions":1832,"interventions":1833},[58],[21,23],[334,335,336,275,337,310,311,338,339],{"trials":1835,"activeCount":67},[],{"trials":1837,"activeCount":67},[],{"trials":1839,"activeCount":67},[],{"intervention":335,"totalTrials":31,"cells":1841},{"EARLY_PHASE1":1842,"PHASE1":1844,"PHASE2":1846,"PHASE3":1852,"PHASE4":1854,"NA":1856},{"trials":1843,"activeCount":67},[],{"trials":1845,"activeCount":67},[],{"trials":1847,"activeCount":67},[1848],{"nctId":324,"briefTitle":325,"status":326,"phases":1849,"primaryCompletion":328,"completion":329,"start":330,"enrollment":331,"conditions":1850,"interventions":1851},[58],[21,23],[334,335,336,275,337,310,311,338,339],{"trials":1853,"activeCount":67},[],{"trials":1855,"activeCount":67},[],{"trials":1857,"activeCount":67},[],{"intervention":337,"totalTrials":31,"cells":1859},{"EARLY_PHASE1":1860,"PHASE1":1862,"PHASE2":1864,"PHASE3":1870,"PHASE4":1872,"NA":1874},{"trials":1861,"activeCount":67},[],{"trials":1863,"activeCount":67},[],{"trials":1865,"activeCount":67},[1866],{"nctId":324,"briefTitle":325,"status":326,"phases":1867,"primaryCompletion":328,"completion":329,"start":330,"enrollment":331,"conditions":1868,"interventions":1869},[58],[21,23],[334,335,336,275,337,310,311,338,339],{"trials":1871,"activeCount":67},[],{"trials":1873,"activeCount":67},[],{"trials":1875,"activeCount":67},[],{"intervention":338,"totalTrials":31,"cells":1877},{"EARLY_PHASE1":1878,"PHASE1":1880,"PHASE2":1882,"PHASE3":1888,"PHASE4":1890,"NA":1892},{"trials":1879,"activeCount":67},[],{"trials":1881,"activeCount":67},[],{"trials":1883,"activeCount":67},[1884],{"nctId":324,"briefTitle":325,"status":326,"phases":1885,"primaryCompletion":328,"completion":329,"start":330,"enrollment":331,"conditions":1886,"interventions":1887},[58],[21,23],[334,335,336,275,337,310,311,338,339],{"trials":1889,"activeCount":67},[],{"trials":1891,"activeCount":67},[],{"trials":1893,"activeCount":67},[],{"intervention":339,"totalTrials":31,"cells":1895},{"EARLY_PHASE1":1896,"PHASE1":1898,"PHASE2":1900,"PHASE3":1906,"PHASE4":1908,"NA":1910},{"trials":1897,"activeCount":67},[],{"trials":1899,"activeCount":67},[],{"trials":1901,"activeCount":67},[1902],{"nctId":324,"briefTitle":325,"status":326,"phases":1903,"primaryCompletion":328,"completion":329,"start":330,"enrollment":331,"conditions":1904,"interventions":1905},[58],[21,23],[334,335,336,275,337,310,311,338,339],{"trials":1907,"activeCount":67},[],{"trials":1909,"activeCount":67},[],{"trials":1911,"activeCount":67},[],{"intervention":1913,"totalTrials":31,"cells":1914},"depo-medroxyprogesterone acetate",{"EARLY_PHASE1":1915,"PHASE1":1917,"PHASE2":1919,"PHASE3":1929,"PHASE4":1931,"NA":1933},{"trials":1916,"activeCount":67},[],{"trials":1918,"activeCount":67},[],{"trials":1920,"activeCount":67},[1921],{"nctId":1922,"briefTitle":1923,"status":220,"phases":1924,"primaryCompletion":1925,"completion":1925,"start":1092,"enrollment":1926,"conditions":1927,"interventions":1928},"NCT01296152","Pharmacokinetic Interactions Between DMPA and LPV\u002Fr Among HIV-Infected Women",[58],"2012-10",25,[15],[1913],{"trials":1930,"activeCount":67},[],{"trials":1932,"activeCount":67},[],{"trials":1934,"activeCount":67},[],{"intervention":1936,"totalTrials":31,"cells":1937},"EFV\u002FFTC\u002FTDF",{"EARLY_PHASE1":1938,"PHASE1":1940,"PHASE2":1942,"PHASE3":1953,"PHASE4":1955,"NA":1957},{"trials":1939,"activeCount":67},[],{"trials":1941,"activeCount":67},[],{"trials":1943,"activeCount":67},[1944],{"nctId":1945,"briefTitle":1946,"status":220,"phases":1947,"primaryCompletion":1621,"completion":1621,"start":1294,"enrollment":1948,"conditions":1949,"interventions":1950},"NCT01403051","High Dose Vitamin D and Calcium for Bone Health in Individuals Initiating HAART",[58],167,[15],[1936,1951,1952],"Calcium Carbonate","Vitamin D3",{"trials":1954,"activeCount":67},[],{"trials":1956,"activeCount":67},[],{"trials":1958,"activeCount":67},[],{"intervention":1951,"totalTrials":31,"cells":1960},{"EARLY_PHASE1":1961,"PHASE1":1963,"PHASE2":1965,"PHASE3":1971,"PHASE4":1973,"NA":1975},{"trials":1962,"activeCount":67},[],{"trials":1964,"activeCount":67},[],{"trials":1966,"activeCount":67},[1967],{"nctId":1945,"briefTitle":1946,"status":220,"phases":1968,"primaryCompletion":1621,"completion":1621,"start":1294,"enrollment":1948,"conditions":1969,"interventions":1970},[58],[15],[1936,1951,1952],{"trials":1972,"activeCount":67},[],{"trials":1974,"activeCount":67},[],{"trials":1976,"activeCount":67},[],{"intervention":1952,"totalTrials":31,"cells":1978},{"EARLY_PHASE1":1979,"PHASE1":1981,"PHASE2":1983,"PHASE3":1989,"PHASE4":1991,"NA":1993},{"trials":1980,"activeCount":67},[],{"trials":1982,"activeCount":67},[],{"trials":1984,"activeCount":67},[1985],{"nctId":1945,"briefTitle":1946,"status":220,"phases":1986,"primaryCompletion":1621,"completion":1621,"start":1294,"enrollment":1948,"conditions":1987,"interventions":1988},[58],[15],[1936,1951,1952],{"trials":1990,"activeCount":67},[],{"trials":1992,"activeCount":67},[],{"trials":1994,"activeCount":67},[],{"intervention":833,"totalTrials":31,"cells":1996},{"EARLY_PHASE1":1997,"PHASE1":1999,"PHASE2":2001,"PHASE3":2007,"PHASE4":2009,"NA":2011},{"trials":1998,"activeCount":67},[],{"trials":2000,"activeCount":67},[],{"trials":2002,"activeCount":67},[2003],{"nctId":824,"briefTitle":825,"status":220,"phases":2004,"primaryCompletion":827,"completion":828,"start":829,"enrollment":830,"conditions":2005,"interventions":2006},[58],[15],[833,374],{"trials":2008,"activeCount":67},[],{"trials":2010,"activeCount":67},[],{"trials":2012,"activeCount":67},[],{"intervention":1074,"totalTrials":31,"cells":2014},{"EARLY_PHASE1":2015,"PHASE1":2017,"PHASE2":2023,"PHASE3":2025,"PHASE4":2027,"NA":2029},{"trials":2016,"activeCount":67},[],{"trials":2018,"activeCount":67},[2019],{"nctId":1066,"briefTitle":1067,"status":220,"phases":2020,"primaryCompletion":827,"completion":1069,"start":1070,"enrollment":1071,"conditions":2021,"interventions":2022},[57],[15,33],[1074,1058,1075],{"trials":2024,"activeCount":67},[],{"trials":2026,"activeCount":67},[],{"trials":2028,"activeCount":67},[],{"trials":2030,"activeCount":67},[],{"intervention":245,"totalTrials":2032,"cells":2033},11,{"EARLY_PHASE1":2034,"PHASE1":2036,"PHASE2":2038,"PHASE3":2044,"PHASE4":2067,"NA":2081},{"trials":2035,"activeCount":67},[],{"trials":2037,"activeCount":67},[],{"trials":2039,"activeCount":67},[2040],{"nctId":218,"briefTitle":219,"status":220,"phases":2041,"primaryCompletion":222,"completion":222,"start":223,"enrollment":224,"conditions":2042,"interventions":2043},[57,58],[15,226],[228,229,208,230,231],{"trials":2045,"activeCount":67},[2046,2055,2059,2063],{"nctId":2047,"briefTitle":2048,"status":220,"phases":2049,"primaryCompletion":2050,"completion":2050,"start":2051,"enrollment":2052,"conditions":2053,"interventions":2054},"NCT00811954","Comparative Study of Three NNRTI-Sparing HAART Regimens",[59],"2013-06","2009-05",1814,[21],[229,336,406,246,244],{"nctId":778,"briefTitle":779,"status":220,"phases":2056,"primaryCompletion":781,"completion":782,"start":783,"enrollment":784,"conditions":2057,"interventions":2058},[59],[18],[286,245,787,230,788],{"nctId":361,"briefTitle":362,"status":220,"phases":2060,"primaryCompletion":364,"completion":364,"start":365,"enrollment":366,"conditions":2061,"interventions":2062},[59],[15],[228,228,336,229,369,370,371,372,373,374],{"nctId":235,"briefTitle":236,"status":220,"phases":2064,"primaryCompletion":238,"completion":238,"start":239,"enrollment":240,"conditions":2065,"interventions":2066},[59],[18],[243,244,208,245,246,247,248],{"trials":2068,"activeCount":67},[2069,2073,2077],{"nctId":397,"briefTitle":398,"status":220,"phases":2070,"primaryCompletion":400,"completion":401,"start":402,"enrollment":403,"conditions":2071,"interventions":2072},[60],[15],[406,384,229,336,407,408],{"nctId":252,"briefTitle":253,"status":220,"phases":2074,"primaryCompletion":255,"completion":256,"start":257,"enrollment":258,"conditions":2075,"interventions":2076},[60],[18],[208,245],{"nctId":277,"briefTitle":278,"status":220,"phases":2078,"primaryCompletion":280,"completion":280,"start":281,"enrollment":282,"conditions":2079,"interventions":2080},[60],[18],[244,285,208,286,245,287],{"trials":2082,"activeCount":67},[2083,2090,2100],{"nctId":2084,"briefTitle":2085,"status":220,"phases":2086,"primaryCompletion":1028,"completion":1028,"start":1094,"enrollment":2087,"conditions":2088,"interventions":2089},"NCT00608569","Determining the Effects of Observed and Self-Administered Drug Regimens in HIV Infected Adults",[61],529,[18],[228,245,788,373,286],{"nctId":2091,"briefTitle":2092,"status":220,"phases":2093,"primaryCompletion":2094,"completion":2095,"start":2096,"enrollment":2097,"conditions":2098,"interventions":2099},"NCT00357552","Safety and Effectiveness of Lopinavir\u002FRitonavir in Individuals Who Have Failed Prior HIV Therapy",[61],"2010-10","2012-05","2008-01",123,[18],[245,787],{"nctId":2101,"briefTitle":2102,"status":220,"phases":2103,"primaryCompletion":2050,"completion":2050,"start":2104,"enrollment":752,"conditions":2105,"interventions":2106},"NCT00851799","Impact of Antiretroviral Therapy on Metabolic, Skeletal, and Cardiovascular Parameters",[],"2009-06",[21],[229,246,244,336,406],{"intervention":787,"totalTrials":8,"cells":2108},{"EARLY_PHASE1":2109,"PHASE1":2111,"PHASE2":2113,"PHASE3":2123,"PHASE4":2133,"NA":2135},{"trials":2110,"activeCount":67},[],{"trials":2112,"activeCount":67},[],{"trials":2114,"activeCount":67},[2115,2119],{"nctId":1267,"briefTitle":1268,"status":326,"phases":2116,"primaryCompletion":1270,"completion":1092,"start":1271,"enrollment":1272,"conditions":2117,"interventions":2118},[58],[18],[1258,787],{"nctId":218,"briefTitle":219,"status":220,"phases":2120,"primaryCompletion":222,"completion":222,"start":223,"enrollment":224,"conditions":2121,"interventions":2122},[57,58],[15,226],[228,229,208,230,231],{"trials":2124,"activeCount":67},[2125,2129],{"nctId":778,"briefTitle":779,"status":220,"phases":2126,"primaryCompletion":781,"completion":782,"start":783,"enrollment":784,"conditions":2127,"interventions":2128},[59],[18],[286,245,787,230,788],{"nctId":361,"briefTitle":362,"status":220,"phases":2130,"primaryCompletion":364,"completion":364,"start":365,"enrollment":366,"conditions":2131,"interventions":2132},[59],[15],[228,228,336,229,369,370,371,372,373,374],{"trials":2134,"activeCount":67},[],{"trials":2136,"activeCount":67},[2137,2141],{"nctId":2084,"briefTitle":2085,"status":220,"phases":2138,"primaryCompletion":1028,"completion":1028,"start":1094,"enrollment":2087,"conditions":2139,"interventions":2140},[61],[18],[228,245,788,373,286],{"nctId":2091,"briefTitle":2092,"status":220,"phases":2142,"primaryCompletion":2094,"completion":2095,"start":2096,"enrollment":2097,"conditions":2143,"interventions":2144},[61],[18],[245,787],{"intervention":336,"totalTrials":8,"cells":2146},{"EARLY_PHASE1":2147,"PHASE1":2149,"PHASE2":2151,"PHASE3":2161,"PHASE4":2171,"NA":2177},{"trials":2148,"activeCount":67},[],{"trials":2150,"activeCount":67},[],{"trials":2152,"activeCount":67},[2153,2157],{"nctId":1567,"briefTitle":1568,"status":220,"phases":2154,"primaryCompletion":1570,"completion":1571,"start":1572,"enrollment":1573,"conditions":2155,"interventions":2156},[58],[1575],[336,1558],{"nctId":324,"briefTitle":325,"status":326,"phases":2158,"primaryCompletion":328,"completion":329,"start":330,"enrollment":331,"conditions":2159,"interventions":2160},[58],[21,23],[334,335,336,275,337,310,311,338,339],{"trials":2162,"activeCount":67},[2163,2167],{"nctId":2047,"briefTitle":2048,"status":220,"phases":2164,"primaryCompletion":2050,"completion":2050,"start":2051,"enrollment":2052,"conditions":2165,"interventions":2166},[59],[21],[229,336,406,246,244],{"nctId":361,"briefTitle":362,"status":220,"phases":2168,"primaryCompletion":364,"completion":364,"start":365,"enrollment":366,"conditions":2169,"interventions":2170},[59],[15],[228,228,336,229,369,370,371,372,373,374],{"trials":2172,"activeCount":67},[2173],{"nctId":397,"briefTitle":398,"status":220,"phases":2174,"primaryCompletion":400,"completion":401,"start":402,"enrollment":403,"conditions":2175,"interventions":2176},[60],[15],[406,384,229,336,407,408],{"trials":2178,"activeCount":67},[2179],{"nctId":2101,"briefTitle":2102,"status":220,"phases":2180,"primaryCompletion":2050,"completion":2050,"start":2104,"enrollment":752,"conditions":2181,"interventions":2182},[],[21],[229,246,244,336,406],{"intervention":286,"totalTrials":291,"cells":2184},{"EARLY_PHASE1":2185,"PHASE1":2187,"PHASE2":2189,"PHASE3":2201,"PHASE4":2207,"NA":2213},{"trials":2186,"activeCount":67},[],{"trials":2188,"activeCount":67},[],{"trials":2190,"activeCount":67},[2191],{"nctId":2192,"briefTitle":2193,"status":220,"phases":2194,"primaryCompletion":2195,"completion":2195,"start":2196,"enrollment":2197,"conditions":2198,"interventions":2199},"NCT01400412","Bone, Immunologic, and Virologic Effects of a Antiretroviral Regimen",[58],"2014-06-30","2012-01-17",262,[15],[406,246,788,286,2200],"Maraviroc",{"trials":2202,"activeCount":67},[2203],{"nctId":778,"briefTitle":779,"status":220,"phases":2204,"primaryCompletion":781,"completion":782,"start":783,"enrollment":784,"conditions":2205,"interventions":2206},[59],[18],[286,245,787,230,788],{"trials":2208,"activeCount":67},[2209],{"nctId":277,"briefTitle":278,"status":220,"phases":2210,"primaryCompletion":280,"completion":280,"start":281,"enrollment":282,"conditions":2211,"interventions":2212},[60],[18],[244,285,208,286,245,287],{"trials":2214,"activeCount":67},[2215],{"nctId":2084,"briefTitle":2085,"status":220,"phases":2216,"primaryCompletion":1028,"completion":1028,"start":1094,"enrollment":2087,"conditions":2217,"interventions":2218},[61],[18],[228,245,788,373,286],{"intervention":406,"totalTrials":291,"cells":2220},{"EARLY_PHASE1":2221,"PHASE1":2223,"PHASE2":2225,"PHASE3":2231,"PHASE4":2237,"NA":2243},{"trials":2222,"activeCount":67},[],{"trials":2224,"activeCount":67},[],{"trials":2226,"activeCount":67},[2227],{"nctId":2192,"briefTitle":2193,"status":220,"phases":2228,"primaryCompletion":2195,"completion":2195,"start":2196,"enrollment":2197,"conditions":2229,"interventions":2230},[58],[15],[406,246,788,286,2200],{"trials":2232,"activeCount":67},[2233],{"nctId":2047,"briefTitle":2048,"status":220,"phases":2234,"primaryCompletion":2050,"completion":2050,"start":2051,"enrollment":2052,"conditions":2235,"interventions":2236},[59],[21],[229,336,406,246,244],{"trials":2238,"activeCount":67},[2239],{"nctId":397,"briefTitle":398,"status":220,"phases":2240,"primaryCompletion":400,"completion":401,"start":402,"enrollment":403,"conditions":2241,"interventions":2242},[60],[15],[406,384,229,336,407,408],{"trials":2244,"activeCount":67},[2245],{"nctId":2101,"briefTitle":2102,"status":220,"phases":2246,"primaryCompletion":2050,"completion":2050,"start":2104,"enrollment":752,"conditions":2247,"interventions":2248},[],[21],[229,246,244,336,406],{"intervention":246,"totalTrials":291,"cells":2250},{"EARLY_PHASE1":2251,"PHASE1":2253,"PHASE2":2255,"PHASE3":2261,"PHASE4":2271,"NA":2273},{"trials":2252,"activeCount":67},[],{"trials":2254,"activeCount":67},[],{"trials":2256,"activeCount":67},[2257],{"nctId":2192,"briefTitle":2193,"status":220,"phases":2258,"primaryCompletion":2195,"completion":2195,"start":2196,"enrollment":2197,"conditions":2259,"interventions":2260},[58],[15],[406,246,788,286,2200],{"trials":2262,"activeCount":67},[2263,2267],{"nctId":2047,"briefTitle":2048,"status":220,"phases":2264,"primaryCompletion":2050,"completion":2050,"start":2051,"enrollment":2052,"conditions":2265,"interventions":2266},[59],[21],[229,336,406,246,244],{"nctId":235,"briefTitle":236,"status":220,"phases":2268,"primaryCompletion":238,"completion":238,"start":239,"enrollment":240,"conditions":2269,"interventions":2270},[59],[18],[243,244,208,245,246,247,248],{"trials":2272,"activeCount":67},[],{"trials":2274,"activeCount":67},[2275],{"nctId":2101,"briefTitle":2102,"status":220,"phases":2276,"primaryCompletion":2050,"completion":2050,"start":2104,"enrollment":752,"conditions":2277,"interventions":2278},[],[21],[229,246,244,336,406],{"intervention":244,"totalTrials":291,"cells":2280},{"EARLY_PHASE1":2281,"PHASE1":2283,"PHASE2":2285,"PHASE3":2287,"PHASE4":2297,"NA":2303},{"trials":2282,"activeCount":67},[],{"trials":2284,"activeCount":67},[],{"trials":2286,"activeCount":67},[],{"trials":2288,"activeCount":67},[2289,2293],{"nctId":2047,"briefTitle":2048,"status":220,"phases":2290,"primaryCompletion":2050,"completion":2050,"start":2051,"enrollment":2052,"conditions":2291,"interventions":2292},[59],[21],[229,336,406,246,244],{"nctId":235,"briefTitle":236,"status":220,"phases":2294,"primaryCompletion":238,"completion":238,"start":239,"enrollment":240,"conditions":2295,"interventions":2296},[59],[18],[243,244,208,245,246,247,248],{"trials":2298,"activeCount":67},[2299],{"nctId":277,"briefTitle":278,"status":220,"phases":2300,"primaryCompletion":280,"completion":280,"start":281,"enrollment":282,"conditions":2301,"interventions":2302},[60],[18],[244,285,208,286,245,287],{"trials":2304,"activeCount":67},[2305],{"nctId":2101,"briefTitle":2102,"status":220,"phases":2306,"primaryCompletion":2050,"completion":2050,"start":2104,"enrollment":752,"conditions":2307,"interventions":2308},[],[21],[229,246,244,336,406],{"intervention":788,"totalTrials":1059,"cells":2310},{"EARLY_PHASE1":2311,"PHASE1":2313,"PHASE2":2315,"PHASE3":2321,"PHASE4":2327,"NA":2329},{"trials":2312,"activeCount":67},[],{"trials":2314,"activeCount":67},[],{"trials":2316,"activeCount":67},[2317],{"nctId":2192,"briefTitle":2193,"status":220,"phases":2318,"primaryCompletion":2195,"completion":2195,"start":2196,"enrollment":2197,"conditions":2319,"interventions":2320},[58],[15],[406,246,788,286,2200],{"trials":2322,"activeCount":67},[2323],{"nctId":778,"briefTitle":779,"status":220,"phases":2324,"primaryCompletion":781,"completion":782,"start":783,"enrollment":784,"conditions":2325,"interventions":2326},[59],[18],[286,245,787,230,788],{"trials":2328,"activeCount":67},[],{"trials":2330,"activeCount":67},[2331],{"nctId":2084,"briefTitle":2085,"status":220,"phases":2332,"primaryCompletion":1028,"completion":1028,"start":1094,"enrollment":2087,"conditions":2333,"interventions":2334},[61],[18],[228,245,788,373,286],{"intervention":373,"totalTrials":28,"cells":2336},{"EARLY_PHASE1":2337,"PHASE1":2339,"PHASE2":2341,"PHASE3":2343,"PHASE4":2349,"NA":2351},{"trials":2338,"activeCount":67},[],{"trials":2340,"activeCount":67},[],{"trials":2342,"activeCount":67},[],{"trials":2344,"activeCount":67},[2345],{"nctId":361,"briefTitle":362,"status":220,"phases":2346,"primaryCompletion":364,"completion":364,"start":365,"enrollment":366,"conditions":2347,"interventions":2348},[59],[15],[228,228,336,229,369,370,371,372,373,374],{"trials":2350,"activeCount":67},[],{"trials":2352,"activeCount":67},[2353],{"nctId":2084,"briefTitle":2085,"status":220,"phases":2354,"primaryCompletion":1028,"completion":1028,"start":1094,"enrollment":2087,"conditions":2355,"interventions":2356},[61],[18],[228,245,788,373,286],{"intervention":2200,"totalTrials":28,"cells":2358},{"EARLY_PHASE1":2359,"PHASE1":2361,"PHASE2":2363,"PHASE3":2369,"PHASE4":2371,"NA":2373},{"trials":2360,"activeCount":67},[],{"trials":2362,"activeCount":67},[],{"trials":2364,"activeCount":67},[2365],{"nctId":2192,"briefTitle":2193,"status":220,"phases":2366,"primaryCompletion":2195,"completion":2195,"start":2196,"enrollment":2197,"conditions":2367,"interventions":2368},[58],[15],[406,246,788,286,2200],{"trials":2370,"activeCount":67},[],{"trials":2372,"activeCount":67},[],{"trials":2374,"activeCount":67},[2375],{"nctId":2376,"briefTitle":2377,"status":220,"phases":2378,"primaryCompletion":2379,"completion":2380,"start":2381,"enrollment":2382,"conditions":2383,"interventions":2384},"NCT00709111","Adding Maraviroc to Antiretroviral Therapy for Suboptimal CD4 T-Cell Recovery Despite Sustained Virologic Suppression",[61],"2009-10","2010-04","2009-01",34,[18],[2200],{"intervention":2386,"totalTrials":31,"cells":2387},"Antiretroviral treatment pause",{"EARLY_PHASE1":2388,"PHASE1":2390,"PHASE2":2392,"PHASE3":2394,"PHASE4":2396,"NA":2398},{"trials":2389,"activeCount":67},[],{"trials":2391,"activeCount":67},[],{"trials":2393,"activeCount":67},[],{"trials":2395,"activeCount":67},[],{"trials":2397,"activeCount":67},[],{"trials":2399,"activeCount":67},[2400],{"nctId":2401,"briefTitle":2402,"status":220,"phases":2403,"primaryCompletion":2404,"completion":2404,"start":2405,"enrollment":2406,"conditions":2407,"interventions":2408},"NCT03001128","Biomarkers to Predict Time to Plasma HIV RNA Rebound",[],"2021-01-29","2017-02-23",61,[15],[2386]]